Functional MRI for Monitoring Progression and Assessing Trends in ILD
ConditionInterstitial Lung Diseases (ILD)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital Heidelberg
About this trial
The main objective of this study is to investigate the utility of functional MRI to differentiate, characterize, and monitor subgroups of ILD. This can be broken down into three specific objectives:
Determine if ILD features observed on high-resolution computed tomography (HRCT), such as ground glass opacities (GGO), are functionally different.
Analyse MRI metrics within each subgroup to determine whether these metrics distinguish different ILDs.
Assess MRI metrics longitudinally to see if these parameters change with disease progression, stability, or reversibility.
Eligibility criteria
Qualifiers
Clinical indication for a routine HRCT because of either newly diagnosed idiopathic pulmonary fibrosis (IPF) or hypersensitivity pneumonitis (HP) or idiopathic non-specific interstitial pneumonia (iNSIP), suspected diagnosis, or follow-up
Capacity to consent
Ability to participate fully in the study (defined by the ability to lie still for the duration of imaging)
Disqualifiers
Pregnancy and breast feeding
Persons under the age of 18 and persons not able to give informed consent
Any medical conditions that could hinder the ability to adhere to the protocol
Any MRI contraindication, including previous allergic reactions to Gd-based MRI contrast material and renal dysfunction (eGFR < 30 ml min/1,73 m2)
Trial design
Treatments tested in this trial
- Lung MRI Protocol with Functional and Contrast-Enhanced Sequences
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
University Hospital Heidelberg
Lead sponsor
German Center for Lung Research
Collaborator
Thoraxklinik-Heidelberg gGmbH
Collaborator
University Hospital Schleswig-Holstein
Collaborator
Source ClinicalTrials.gov